متعة السوق تعود ......ورجوعنا مع هذا السهم

stockolic

عضو نشط
التسجيل
18 مايو 2009
المشاركات
466
بدأ السوق يتعافى فعلا وبدأنا نشهد صعود بعض الاسهم ولكن بانتقائيه

هذا السهم تحرك البارحه بقوه في اخر ساعتين من جلسة امس بدون اخبار

الشركه لديها موافقه من ال FDA على اختبار للاورام والسرطان

اعلى سعر للشركه منذ ال 52 اسبوع هو 2.5 دولار

التحليل الفني للسهم يقول مافيه مقاومه لغاية الدولارين

http://www.youtube.com/watch?v=j89QcAF5Kog&feature=player_embedded


اعتقد والله العالم ان ان هناك ترقب لاعلان كبير من قبل الشركه ( شراكه او عروض شراء)


الشركه هي

RPC

وسعر اغلاق امس هو 1.29 دولار


وبالتوفيق للجميع
 

stockolic

عضو نشط
التسجيل
18 مايو 2009
المشاركات
466
باين راح تكون بدايه قويه


ارتفاع في البري ماركت


1.5
 

ابو مياسم

عضو نشط
التسجيل
27 مارس 2004
المشاركات
262
الإقامة
السعوديه
يوجد خبر اليوم

Filing Sends Radient Shares Higher
Filing Sends Radient Shares Higher
Feb. 15, 2011 (Baystreet.ca) --

Shares of Radient Pharmaceuticals (AMEX:RPC) rose 13% on Monday following a disclosure from Heights Capital Management that Capital Ventures International had recently taken a 5.7% stake in the company. In a statement filed with the SEC; via Schedule 13G; it was noted that the same firm who is noted as an early investor in Dendreon Corporation (Nadaq:DNDN) took a large position in the company. By filing a Form 13G, a party discloses that it own between 5% and 20% in the company. It must also be clearly understood that the party acquiring the stake in the company is only a passive investor, and does not intend to exert control.


In addition, the Comtex News SmarTrend system, which analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time, noted that shares of the company might be set for a rebound.





Upcoming catalysts in the stock include results from a major validation study being conducted with the Mayo Clinic. Positive clinical data from that study, which will compare Radient's early cancer detection technology against current testing methods, could send shares significantly higher. Radient Pharmaceuticals engages in the research, development, manufacture, and marketing of diagnostic and skin care products. It offers ONKO-SURE, a proprietary in-vitro diagnostic cancer test, which is used for the detection and/or monitoring of lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, and pancreatic cancers.




Source: Accesswire (February 15, 2011 - 8:53 AM EST)

News by QuoteMedia

هل هو خبر ايجابي او سلبي
 
يجب تسجيل الدخول أو التسجيل كي تتمكن من الرد هنا.
أعلى